Kristina Callis Duffin

Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking.

Multiple Loci within the major histocompatibility complex confer risk of psoriasis.

Obesity in early adulthood as a risk factor for psoriatic arthritis.

Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.

Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.

Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.

Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.

Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.

Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply.

Practice GAPS: preventing and detecting antibodies to anti-tumor necrosis factor agents: gaps in practice or in evidence?

Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

Desired Improvement Tool (DIT): A tool to assess desire for improvement in psoriasis patients.

Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis.

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series.

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA.

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.

Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.

Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases.

Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.

Advances and Controversies in Our Understanding of Guttate and Plaque Psoriasis.

PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries.